FY2024 EPS Estimates for AxoGen Increased by Leerink Partnrs

AxoGen, Inc. (NASDAQ:AXGN - Free Report) - Research analysts at Leerink Partnrs upped their FY2024 earnings estimates for shares of AxoGen in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now anticipates that the medical equipment provider will post earnings per share of ($0.31) for the year, up from their prior forecast of ($0.32). The consensus estimate for AxoGen's current full-year earnings is ($0.30) per share. Leerink Partnrs also issued estimates for AxoGen's Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.06) EPS, FY2026 earnings at $0.17 EPS, FY2027 earnings at $0.26 EPS and FY2028 earnings at $0.34 EPS.

Several other analysts have also recently issued reports on AXGN. StockNews.com raised shares of AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. JMP Securities increased their target price on shares of AxoGen from $17.00 to $20.00 and gave the stock a "market outperform" rating in a report on Friday, August 9th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $15.00.

AxoGen Trading Up 0.7 %

Shares of NASDAQ:AXGN traded up $0.09 during mid-day trading on Wednesday, reaching $13.70. 10,087 shares of the company were exchanged, compared to its average volume of 398,983. AxoGen has a 1 year low of $5.55 and a 1 year high of $15.90. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.74 and a quick ratio of 2.47. The firm's 50-day simple moving average is $13.73 and its 200 day simple moving average is $10.68. The firm has a market cap of $602.94 million, a price-to-earnings ratio of -42.53 and a beta of 1.13.

Hedge Funds Weigh In On AxoGen

Several hedge funds have recently added to or reduced their stakes in the stock. Quest Partners LLC grew its position in shares of AxoGen by 23,066.7% in the 3rd quarter. Quest Partners LLC now owns 2,085 shares of the medical equipment provider's stock valued at $29,000 after buying an additional 2,076 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of AxoGen during the third quarter worth about $56,000. Koss Olinger Consulting LLC purchased a new stake in shares of AxoGen in the 2nd quarter valued at about $75,000. Lazard Asset Management LLC boosted its position in shares of AxoGen by 30.1% in the 1st quarter. Lazard Asset Management LLC now owns 11,539 shares of the medical equipment provider's stock valued at $93,000 after purchasing an additional 2,671 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in AxoGen during the 2nd quarter worth approximately $125,000. 80.29% of the stock is currently owned by hedge funds and other institutional investors.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.